Zenas BioPharma Statistics
Total Valuation
Zenas BioPharma has a market cap or net worth of $473.56 million. The enterprise value is $162.41 million.
Important Dates
The next estimated earnings date is Tuesday, June 17, 2025, before market open.
| Earnings Date | Jun 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zenas BioPharma has 41.83 million shares outstanding. The number of shares has increased by 1,408.82% in one year.
| Current Share Class | 41.83M |
| Shares Outstanding | 41.83M |
| Shares Change (YoY) | +1,408.82% |
| Shares Change (QoQ) | -0.31% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 49.61% |
| Float | 20.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.55 |
| Forward PS | n/a |
| PB Ratio | 1.67 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.47, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.47 |
| Quick Ratio | 6.39 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -115.47% and return on invested capital (ROIC) is -71.22%.
| Return on Equity (ROE) | -115.47% |
| Return on Assets (ROA) | -56.70% |
| Return on Invested Capital (ROIC) | -71.22% |
| Return on Capital Employed (ROCE) | -61.00% |
| Revenue Per Employee | $115,385 |
| Profits Per Employee | -$1.25M |
| Employee Count | 130 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zenas BioPharma has paid $224,000 in taxes.
| Income Tax | 224,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 9.77 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 56.04 |
| Average Volume (20 Days) | 193,505 |
Short Selling Information
The latest short interest is 4.86 million, so 11.61% of the outstanding shares have been sold short.
| Short Interest | 4.86M |
| Short Previous Month | 4.92M |
| Short % of Shares Out | 11.61% |
| Short % of Float | 23.18% |
| Short Ratio (days to cover) | 22.79 |
Income Statement
In the last 12 months, Zenas BioPharma had revenue of $15.00 million and -$162.76 million in losses. Loss per share was -$7.00.
| Revenue | 15.00M |
| Gross Profit | -136.41M |
| Operating Income | -173.64M |
| Pretax Income | -54.46M |
| Net Income | -162.76M |
| EBITDA | -173.51M |
| EBIT | -173.64M |
| Loss Per Share | -$7.00 |
Full Income StatementBalance Sheet
The company has $312.38 million in cash and $1.23 million in debt, giving a net cash position of $311.15 million or $7.44 per share.
| Cash & Cash Equivalents | 312.38M |
| Total Debt | 1.23M |
| Net Cash | 311.15M |
| Net Cash Per Share | $7.44 |
| Equity (Book Value) | 284.32M |
| Book Value Per Share | 6.80 |
| Working Capital | 268.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$137.62 million and capital expenditures -$127,000, giving a free cash flow of -$137.75 million.
| Operating Cash Flow | -137.62M |
| Capital Expenditures | -127,000 |
| Free Cash Flow | -137.75M |
| FCF Per Share | -$3.29 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,157.60% |
| Pretax Margin | -1,083.58% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zenas BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,408.82% |
| Shareholder Yield | -1,408.82% |
| Earnings Yield | -34.37% |
| FCF Yield | -29.09% |
Dividend DetailsAnalyst Forecast
The average price target for Zenas BioPharma is $32.29, which is 185.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.29 |
| Price Target Difference | 185.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zenas BioPharma has an Altman Z-Score of 3.66 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.66 |
| Piotroski F-Score | 2 |